- Home
- ELS vs MDGL Comparison
ELS vs MDGL Comparison
Compare ELS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELS | MDGL |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.0B |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ELS | MDGL |
|---|---|---|
| Price | $63.87 | $521.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $70.85 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 1.2M | 349.8K |
| Earning Date | 04-20-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | 2.55 | ★ 41.32 |
| EPS | ★ 2.01 | N/A |
| Revenue | ★ $1,531,382,000.00 | $180,133,000.00 |
| Revenue This Year | $3.97 | $58.39 |
| Revenue Next Year | $4.69 | $47.10 |
| P/E Ratio | $31.87 | ★ N/A |
| Revenue Growth | ★ 0.34 | N/A |
| 52 Week Low | $57.63 | $265.00 |
| 52 Week High | $69.00 | $615.00 |
Technical Indicators
Market Signals| Indicator | ELS | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 62.15 |
| Support Level | $58.56 | $411.87 |
| Resistance Level | $68.73 | $610.00 |
| Average True Range (ATR) | 1.00 | 26.99 |
| MACD | 0.10 | 3.75 |
| Stochastic Oscillator | 66.45 | 64.35 |
Price Performance
Historical ComparisonAbout ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the US with a higher concentration in the Sunbelt; 38% of the company's properties are in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.